Psilocybin Emerging Drug Insight

“Psilocybin Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Psilocybin for Anorexia Nervosa in the 7MM. A detailed picture of the Psilocybin for Anorexia Nervosa in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Psilocybin for Anorexia Nervosa. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Psilocybin market forecast, analysis for Anorexia Nervosa in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Anorexia Nervosa.

Drug Summary

Psilocybin is a serotonin 2 receptor agonist, being developed by COMPASS Pathways, for treatment-resistant depression, including major depressive disorder, depressive disorders, bipolar depression, body dysmorphic disorder (somatoform disorders in developmental table), and anorexia nervosa. It is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms. In AN, aberrant serotonergic activity and reduced synaptic plasticity-related brain-derived neurotrophic factor (BDNF) serum concentrations are thought to contribute to psychopathology. A characterized by cognitive rigidity and experiential or emotional avoidance, and these traits have been demonstrated to change following a meaningful psychedelic experience where the experience of intense emotional states is an important part of the therapeutic process.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the Psilocybin description, mechanism of action, dosage and administration, research and development activities in Anorexia Nervosa.
•  Elaborated details on Psilocybin regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the Psilocybin research and development activity in Anorexia Nervosa details across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around Psilocybin.
•  The report contains forecasted sales of Psilocybin for Anorexia Nervosa till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Anorexia Nervosa.
•  The report also features the SWOT analysis with analyst views for Psilocybin in Anorexia Nervosa.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Psilocybin Analytical Perspective by DelveInsight

• In-depth Psilocybin Market Assessment

This report provides a detailed market assessment of Psilocybin in Anorexia Nervosa in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026-2032.

•  Psilocybin Clinical Assessment

The report provides the clinical trials information of Psilocybin for Anorexia Nervosa covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Anorexia Nervosa is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Psilocybin dominance.
•  Other emerging products for Anorexia Nervosa are expected to give tough market competition to Psilocybin and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Psilocybin in Anorexia Nervosa.
•  Our in-depth analysis of the forecasted sales data of Psilocybin from 2026-2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Psilocybin in Anorexia Nervosa.

Key Questions

•  What is the product type, route of administration and mechanism of action of Psilocybin?
•  What is the clinical trial status of the study related to Psilocybin in Anorexia Nervosa and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Psilocybin development?
•  What are the key designations that have been granted to Psilocybin for Anorexia Nervosa?
•  What is the forecasted market scenario of Psilocybin for Anorexia Nervosa?
•  What are the forecasted sales of Psilocybin in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Anorexia Nervosa and how are they giving competition to Psilocybin for Anorexia Nervosa?
•  Which are the late-stage emerging therapies under development for the treatment of Anorexia Nervosa?